Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid ONIS control number.

POV	VER OF ATTORNE	Y TO PROSECU	TE APP	LICATIONS	BEFORE THE	USPTO
hereby rev 37 CFR 3.7	voke ali previous powers	of attorney given in	the appli	cation identifie	ed in the attached s	latement under
hereby ap						
राज्या	oners associated with the Cus	tomer Number:	45511			
OR						
	oner(s) named balow (if more	there too notant resultions	om and to be	nomed then a c	natural sumbarment b	a coadh
	nuer(a) names oanow (n mote	man ren paran praemore	els ale to be	s named, men a C	nsternar militaat minst n	a useu).
•	Name	Registra			Name	Registration
		Numb	BI I			Number
-						
<u> </u>						
ny and all pa	or agent(s) to represent the unterk applications assigned only	y to the undersigned according	niled States ording to the	Patent and Trade USPTO assignm	mark Office (USPTO) in tent records or assignm	connection with ent documents
uached to th	is form in accordance with 37	CFR 3./3(D).				
OR Firm or Individual	r ual Name					
City		To	State	·	I Zip	
			Jidio		- Cip	
Country					-	
Telephone				Email		
						A4.
	ne and Address:					
	sen Pharmaceutica	N.V.			•	
Turn	houtseweg 30 '					
		_				
	se, Belgium B-234	10			-	
Beer:	se, Belgium B-234		ED 2 7211) (Form PTO/S	thatevirus ar 2019:	ie rominad to be
Beer: A copy of ti iled in eacl	se, Belgium B-234 his form, together with a h application in which th	statement under 37 (is form is used. The	statement	under 37 CFR	3.75(b) may be con	pleted by one o
Beer: A copy of the caption of the c	se, Belgium B-234 his form, together with a h application in which the	statement under 37 (is form is used. The orm if the appointed	statement practitions	under 37 CFR or is authorized	3.75(b) may be con	pleted by one o
Beer: A copy of the copy of the practition	se, Belgium B-234 his form, together with a h application in which th	statement under 37 (is form is used. The orm if the appointed (which this Power of	statement practitions Attorney i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con	pleted by one o
Beer: A copy of ti filed in each	se, Belgium B-234 his form, together with a h application in which the oners appointed in this formation in	statement under 37 (is form is used. The orm if the appointed a which this Power of SIGNATURE of	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con I to act on behalf of	pleted by one o the assignee.
Beer: A copy of ti filed in each	se, Belgium B-234 his form, together with a h application in which the	statement under 37 (is form is used. The orm if the appointed a which this Power of SIGNATURE of	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con I to act on behalf of	pleted by one o the assignee.
Beer: A copy of ti iled in each the practition and must id	se, Belgium B-234 his form, together with a h application in which the oners appointed in this formation in	statement under 37 (is form is used. The orm if the appointed a which this Power of SIGNATURE of	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be conditionally of the assignment on behalf of the assignment of the as	ipleted by one of the assignee.
Beer: A copy of the copy of the practition	his form, together with a happlication in which the chart appointed in this federality the application in The individual whose si	statement under 37 (is form is used. The orm if the appointed which this Power of SIGNATURE of gnature and title is supply	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con to behalf of the assign Dato 5	ipleted by one of the assignee.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or oftain a benefit by the public writch is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.12. This collection is estimated to take 3 minutes to complete, including gathering; preparing, and submitting the completed application form to the USPTO. Time we vary depending upon the individual case. Any comments on the amount of time you require to complete this form endor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner:
Application No./Patent No.: 10/560,485 Filed/Issue Date: December 12, 2005
Entitled: 5HT4-ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES
JANSSEN PHARMACEUTICA N.V., a CORPORATION (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)
in the patent application/patent identified above by virtue of either:
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: INVENTORS J. BOSMANS AND J. GIJSEN To: JANSSEN PHARMACEUTICA N.V. The document was recorded in the United States Patent and Trademark Office at Reel 017401 , Frame 09/3 , or for which a copy thereof is attached.
2. From: INVENTOR L. MEVELLEC To: JANSSEN-CILAG
The document was recorded in the United States Patent and Trademark Office at Reel _017446, Frame _0203, or for which a copy thereof is attached.
3. From: JANSSEN-CILAG To: JANSSEN PHARMACEUTICA N.V.
The document was recorded in the United States Patent and Trademark Office at Reel 017401, Frame 0955, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (<i>i.e.</i> , a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
/David N. Farsiou/ AUGUST 21, 2007
Signature Date
David N. Farsiou 215-568-3100
Printed or Typed Name Telephone Number
ATTORNEY FOR APPLICANT/REG. NO. 44,104 Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid ONIS control number.

POV	VER OF ATTORNE	Y TO PROSECU	TE APP	LICATIONS	BEFORE THE	USPTO
hereby rev 37 CFR 3.7	voke ali previous powers	of attorney given in	the appli	cation identifie	ed in the attached s	latement under
hereby ap						
राज्या	oners associated with the Cus	tomer Number:	45511			
OR						
	oner(s) named balow (if more	there too notant resultions	om and to be	nomed then a c	natural sumbar much b	a coadh
	nuer(a) names oanow (n mote	man ren paran praemore	els ale to be	s named, men a C	nsternar militaat minst n	a useu).
•	Name	Registra			Name	Registration
		Numb	BI I			Number
-						
<u> </u>						
ny and all pa	or agent(s) to represent the unterk applications assigned only	y to the undersigned according	niled States ording to the	Patent and Trade USPTO assignm	mark Office (USPTO) in tent records or assignm	connection with ent documents
uached to th	is form in accordance with 37	CFR 3./3(D).				
OR Firm or Individual	r ual Name					
City		To	State	·	I Zip	
			Jidio		- Cip	
Country					-	
Telephone				Email		
						A4.
	ne and Address:					
	sen Pharmaceutica	N.V.			•	
Turn	houtseweg 30 '					
		_				
	se, Belgium B-234	10			-	
Beer:	se, Belgium B-234		ED 2 7211) (Form PTO/S	thatevirus ar 2019:	ie rominad to be
Beer: A copy of ti iled in eacl	se, Belgium B-234 his form, together with a h application in which th	statement under 37 (is form is used. The	statement	under 37 CFR	3.75(b) may be con	pleted by one o
Beer: A copy of the caption of the c	se, Belgium B-234 his form, together with a h application in which the	statement under 37 (is form is used. The orm if the appointed	statement practitions	under 37 CFR or is authorized	3.75(b) may be con	pleted by one o
Beer: A copy of the copy of the practition	se, Belgium B-234 his form, together with a h application in which th	statement under 37 (is form is used. The orm if the appointed (which this Power of	statement practitions Attorney i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con	pleted by one o
Beer: A copy of ti filed in each	se, Belgium B-234 his form, together with a h application in which the oners appointed in this formation in	statement under 37 (is form is used. The orm if the appointed a which this Power of SIGNATURE of	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con I to act on behalf of	pleted by one o the assignee.
Beer: A copy of ti filed in each	se, Belgium B-234 his form, together with a h application in which the	statement under 37 (is form is used. The orm if the appointed a which this Power of SIGNATURE of	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con I to act on behalf of	pleted by one o the assignee.
Beer: A copy of ti iled in each the practition and must id	se, Belgium B-234 his form, together with a h application in which the oners appointed in this formation in	statement under 37 (is form is used. The orm if the appointed a which this Power of SIGNATURE of	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be conditionally of the assignment on behalf of the assignment of the as	ipleted by one of the assignee.
Beer: A copy of the copy of the practition	his form, together with a happlication in which the chart appointed in this federality the application in The individual whose si	statement under 37 (is form is used. The orm if the appointed which this Power of SIGNATURE of gnature and title is supply	statement practitions Attornay i	under 37 CFR or is authorized s to be filed.	3.75(b) may be con to behalf of the assign Dato 5	ipleted by one of the assignee.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or oftain a benefit by the public writch is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.12. This collection is estimated to take 3 minutes to complete, including gathering; preparing, and submitting the completed application form to the USPTO. Time we vary depending upon the individual case. Any comments on the amount of time you require to complete this form endor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner:
Application No./Patent No.: 10/560,485 Filed/Issue Date: December 12, 2005
Entitled: 5HT4-ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES
JANSSEN PHARMACEUTICA N.V., a CORPORATION (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)
in the patent application/patent identified above by virtue of either:
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: INVENTORS J. BOSMANS AND J. GIJSEN To: JANSSEN PHARMACEUTICA N.V. The document was recorded in the United States Patent and Trademark Office at Reel 017401 , Frame 09/3 , or for which a copy thereof is attached.
2. From: INVENTOR L. MEVELLEC To: JANSSEN-CILAG
The document was recorded in the United States Patent and Trademark Office at Reel _017446, Frame _0203, or for which a copy thereof is attached.
3. From: JANSSEN-CILAG To: JANSSEN PHARMACEUTICA N.V.
The document was recorded in the United States Patent and Trademark Office at Reel 017401, Frame 0955, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (<i>i.e.</i> , a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
/David N. Farsiou/ AUGUST 21, 2007
Signature Date
David N. Farsiou 215-568-3100
Printed or Typed Name Telephone Number
ATTORNEY FOR APPLICANT/REG. NO. 44,104 Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.